MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/13506129.2022.2056011

Медицинская библиотека · Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2022

CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis.

Takahashi Yusuke, Ohashi Nobuhiko, Takasone Ken, Yoshinaga Tsuneaki, Yazaki Masahide, Roberts Michael, Glidden Paul F, Sekijima Yoshiki

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: To investigate the effect of tolcapone on cerebrospinal fluid (CSF) transthyretin (TTR) tetramer stability in patients with hereditary transthyretin (ATTRv) amyloidosis.

METHODS

A total of 9 patients were enrolled in the study (3 men, 50.3 ± 14.4 years old). Three patients had central nervous system (CNS) involvement. Patients were assigned to receive tolcapone 300 mg/day or 600 mg/day for 7 days. Plasma and CSF were collected at baseline and 2 h after the final tolcapone dose.

RESULTS

The mean CSF tolcapone and 3-O-Methyltolcapone (3-OMT) concentration were 39.4 ± 36.3 ng/mL and 26.0 ± 4.9 ng/mL, respectively, after 7 days of tolcapone dosing. Tolcapone and 3-OMT were detected in the CSF of patients with or without CNS symptoms. The mean total study drug (tolcapone + 3-OMT) to TTR molar ratio in CSF was 1.15 ± 0.59. Orally administered tolcapone significantly increased CSF TTR concentration and decreased monomer content under semi-denaturing conditions. Eight adverse events (AEs) were reported in 6 patients. All AEs were mild in severity and resolved.

CONCLUSIONS

Tolcapone was able to cross the blood brain-barrier, highlighting its potential to decrease CNS manifestations of ATTRv amyloidosis. Tolcapone was well tolerated by patients with ATTRv amyloidosis.

Для цитирования: Takahashi Yusuke, Ohashi Nobuhiko, Takasone Ken, Yoshinaga Tsuneaki, Yazaki Masahide, Roberts Michael, Glidden Paul F, Sekijima Yoshiki. CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis.. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2022. DOI: 10.1080/13506129.2022.2056011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.